Syndax Q1 net loss $41.1M; on track for two pivotal readouts and NDA/BLA filings in 2023

Syndax Pharmaceuticals Inc

2023-Q1 EPS reported -$0.59

Net loss of $41.1M ($0.59/sh) vs $37.2M ($0.63/sh) YoY; cash $449M as of Mar 31, 2023.
Topline data from AGAVE-201 (axatilimab in cGVHD) expected mid-2023; BLA filing by end of 2023.
Topline data from AUGMENT-101 (revumenib in KMT2Ar acute leukemia) expected Q3 2023; NDA filing by end of 2023.
Alexander Nolte resigned as VP, CAO; CFO Keith Goldan appointed as Principal Accounting Officer.
Full-year 2023 R&D expense guidance reaffirmed at $160-175M; total op ex $225-240M.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alexander Nolte

Vice President, Chief Accounting Officer

SNDX · Syndax Pharmaceuticals Inc

Effective: 2023-05-05
Successor: Keith A. Goldan
Filed: May 8, 2023, 7:59 PM ET

Effective May 5, 2023, Alexander Nolte resigned from his positions as the Company’s Vice President, Chief Accounting Officer and its Principal Accounting Officer, in order to pursue another opportunity.

Appointed

Keith A. Goldan

Principal Accounting Officer

SNDX · Syndax Pharmaceuticals Inc

Filed: May 8, 2023, 7:59 PM ET

The Company has appointed Keith A. Goldan, the Company’s Chief Financial Officer, Treasurer and its Principal Financial Officer, as its Principal Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Syndax Pharmaceuticals Inc reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 8, 2023, Syndax Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexander Nolte resigned as Vice President, Chief Accounting Officer at Syndax Pharmaceuticals Inc.

Action: resigned
Role: Vice President, Chief Accounting Officer

Exact text from the filing

Effective May 5, 2023, Alexander Nolte resigned from his positions as the Company’s Vice President, Chief Accounting Officer and its Principal Accounting Officer, in order to pursue another opportunity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith A. Goldan was appointed as Principal Accounting Officer at Syndax Pharmaceuticals Inc.

Action: appointed
Role: Principal Accounting Officer

Exact text from the filing

The Company has appointed Keith A. Goldan, the Company’s Chief Financial Officer, Treasurer and its Principal Financial Officer, as its Principal Accounting Officer.

View on SEC.gov

Browse all earnings releases →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-018794

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.